GSK3B and Alzheimer disease: The predicted targets GSK3β (P49841), CLK1 (P49759), CK1δ (P48730), and DYRK1B (Q9Y463) have been reported in the literature as a possible approach to develop drugs to palliate AD [27,75,125,127,131].